Roth Capital Downgrades Somaxon Pharma (SOMX) to Neutral
SOMX Hot Sheet
Rating Summary:1 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Roth Capital downgraded Somaxon Pharma (NASDAQ: SOMX) from Buy to Neutral, price target lowered from $3 to $0.75.
For an analyst ratings summary and ratings history on Somaxon Pharma click here. For more ratings news on Somaxon Pharma click here.
Shares of Somaxon Pharma closed at $0.58 yesterday, with a 52 week range of $0.42-$3.26.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on Somaxon Pharma click here. For more ratings news on Somaxon Pharma click here.
Shares of Somaxon Pharma closed at $0.58 yesterday, with a 52 week range of $0.42-$3.26.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates
- UBS Maintains a 'Neutral' on VeriFone (PAY); Europe Demand Healthy, but FX Emerges as Headwind
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
